IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
FEDERAL LOBBYING RECORDS

LOBBYING FILINGS AND MARKET CONTEXT

Indexed federal lobbying filings mapped to clients, registrants, and public-company tickers. Transaction dates are compared with filing periods to identify date-proximity review flags. Proximity does not establish coordination, influence, or wrongdoing.

Filings tracked
20,641
thru 2026-07-15
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,260
paying companies
Tickers targeted
1,219
public companies

Clients by reported amount

Mapped tickers by reported amount

#TickerFilingsTotal $
1META
Meta Platforms Inc.
134$50.3M
2PFE
Pfizer Inc.
89$48.7M
3GM
General Motors Company
103$48.4M
4V
Visa Inc.
47$37.7M
5AMZN
Amazon.com Inc.
82$35.4M
6LMT
Lockheed Martin Corporation
92$29.5M
7FDX
FedEx Corporation
83$28.4M
8LLY
Eli Lilly and Company
88$28.4M
9AMGN
Amgen Inc.
100$28.0M
10MRK
Merck & Co. Inc.
92$27.5M
11AAPL
Apple Inc.
66$27.0M
12GOOGL
Alphabet Inc. Class A
128$26.8M
13MO172$26.4M
14SO
Southern Company
110$26.2M
15UNH
UnitedHealth Group Inc.
68$24.0M
16VZ
Verizon Communications Inc.
119$23.8M
17TMUS170$22.9M
18CHTR142$22.8M
19GD
General Dynamics Corporation
131$22.6M
20T
AT&T Inc.
137$21.7M
21ORCL
Oracle Corporation
135$20.8M
22CMCSA
Comcast Corporation
142$20.5M
23OXY
Occidental Petroleum Corporation
38$20.1M
24CI
The Cigna Group
64$19.9M
25MSFT
Microsoft Corporation
126$19.3M

🆕 Filtered Filings · DANAHER CORPORATION

clear filters
DateTickerClientRegistrantAmountIssue
2026-07-06DHRDANAHER CORPORATIONDENTONS US LLP$0
2026-05-18DHRDANAHER CORPORATIONLEWIS-BURKE ASSOCIATES, LLC$0Issues pertaining to the regulation of cell and gene therapy products; Issues pertaining to the biomedical research enterprise Issues pertaining to the regulation of cell and gene therapy products; Issues pertaining to the biomedical research enterprise
2026-04-20DHRDANAHER CORPORATIONDANAHER CORPORATION$190KIssues related to biotechnology, cell and gene therapy General issues related to tariffs Issues related to decarbonization
2026-04-20DHRDANAHER CORPORATIONAKIN GUMP STRAUSS HAUER & FELD$60KIssues related to a manufacturing rebate program for domestic production of life sciences products.
2026-04-20DHRDANAHER CORPORATIONFULCRUM PUBLIC AFFAIRS LLC$50KIssues Related to biotech and bio manufacturing.
2026-03-26DHRDANAHER CORPORATIONDENTONS US LLP$0
2026-03-04DHRDANAHER CORPORATIONFULCRUM PUBLIC AFFAIRS LLC$40KIssues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing.
2026-01-20DHRDANAHER CORPORATIONAKIN GUMP STRAUSS HAUER & FELD$60KIssues related to a manufacturing rebate program for domestic production of life sciences products.
2026-01-20DHRDANAHER CORPORATIONFULCRUM PUBLIC AFFAIRS LLC$50KIssues Related to biotech and bio manufacturing.
2026-01-19DHRDANAHER CORPORATIONDANAHER CORPORATION$160KIssues related to biotechnology, cell and gene therapy General issues related to tariffs
2026-01-13DHRDANAHER CORPORATIONDENTONS US LLP$0
2025-10-20DHRDANAHER CORPORATIONDANAHER CORPORATION$270KIssues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to tariffs Discussions regarding export controls
2025-10-20DHRDANAHER CORPORATIONFULCRUM PUBLIC AFFAIRS LLC$50KIssues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing.
2025-10-20DHRDANAHER CORPORATIONAKIN GUMP STRAUSS HAUER & FELD$30K
2025-10-18DHRDANAHER CORPORATIONAKIN GUMP STRAUSS HAUER & FELD$0Issues related to tariffs on the life sciences industry.
2025-10-15DHRDANAHER CORPORATIONDENTONS US LLP$60KEducation campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch.
2025-10-13DHRDANAHER CORPORATIONMERCURY PUBLIC AFFAIRS, LLC$70KIssues related to science & biotechnology products
2025-07-31DHRDANAHER CORPORATIONMERCURY PUBLIC AFFAIRS, LLC$111KIssues related to science & biotechnology products
2025-07-21DHRDANAHER CORPORATIONDANAHER CORPORATION$220KIssues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to tariffs
2025-07-21DHRDANAHER CORPORATIONFULCRUM PUBLIC AFFAIRS LLC$40KIssues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing.
2025-07-17DHRDANAHER CORPORATIONDENTONS US LLP$70KEducation campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch.
2025-04-21DHRDANAHER CORPORATIONDANAHER CORPORATION$230KIssues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to tariffs
2025-04-21DHRDANAHER CORPORATIONFULCRUM PUBLIC AFFAIRS LLC$40KIssues Related to biotech and bio manufacturing. Issues Related to biotech and bio manufacturing.
2025-04-16DHRDANAHER CORPORATIONMERCURY PUBLIC AFFAIRS, LLC$50KIssues related to science & biotechnology products
2025-04-12DHRDANAHER CORPORATIONDENTONS US LLP$100KEducation campaign with policymakers related to life sciences and biotechnology issues. Tax and tariff proposals under review and consideration by Congress and Executive Branch.
2025-02-27DHRDANAHER CORPORATIONMERCURY PUBLIC AFFAIRS, LLC$0Issues related to life science & biotechnology products
2025-01-21DHRDANAHER CORPORATIONDANAHER CORPORATION$180KDiscussions regarding National Biotechnology and Biomanufacturing Initiative - Executive Order 14081 Issues related to genomic medicines Issues related to biotechnology, cell and gene therapy General issues related to antitrust laws General issues related to permanent normal trade relations
2025-01-21DHRDANAHER CORPORATIONFULCRUM PUBLIC AFFAIRS LLC$40KIssues related to biotechnology, bio manufacturing Issues Related to biotech and bio manufacturing